Pharming receives government grant to develop human lactoferrin for inflammatory bowel diseases

19-Jun-2009 - Netherlands

Pharming Group NV announced that it has initiated a two-year food & Nutrition Delta (FND) innovation project to further develop human lactoferrin (hLF) as a nutritional product to manage inflammatory bowel diseases (IBD).

The goal of this program is to demonstrate safety and effectiveness of hLF as a component of functional foods for maintaining remission periods in patients with IBD. Pharming is collaborating with NIZO food research BV (Ede), the Maastricht University Medical Centre (Division of Gastroenterology-Hepatology), NUTRIM School for Nutrition, Toxicology and Metabolism (Maastricht) and TNO (Zeist). A € 400.000 subsidy was granted by FND, which is an Innovation Programme of the Dutch Ministry of Economic Affairs, executed by its agency SenterNovem. The subsidy will cover a significant portion of the costs of the early phases of the project.

As hLF has anti-infective and anti-inflammatory properties, it could provide an effective nutritional support for IBD-patients potentially preventing or delaying periods of relapse of the disease. Pharming's human lactoferrin might also be beneficial in alleviating or preventing symptoms of other chronic or acute intestinal diseases such as Irritable bowel syndrome (IBS or spastic colon) and Traveler's diarrhea.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances